{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:33:11Z","timestamp":1744716791234,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":81,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642282959"},{"type":"electronic","value":"9783642282966"}],"license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/82_2011_170","type":"book-chapter","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T04:37:25Z","timestamp":1312605445000},"page":"119-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["JAK-Mutant Myeloproliferative Neoplasms"],"prefix":"10.1007","author":[{"given":"Ross L.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,7]]},"reference":[{"key":"170_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","volume":"70","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O et al (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:447\u2013452","journal-title":"Cancer Res"},{"issue":"5","key":"170_CR2","first-page":"769","volume":"19","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O et al (2011a) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 19(5):769\u2013780","journal-title":"Leukemia"},{"key":"170_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/leu.2011.82","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O et al (2011b) DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25:1219\u20131220","journal-title":"Leukemia"},{"issue":"17","key":"170_CR4","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","volume":"115","author":"H Akada","year":"2010","unstructured":"Akada H et al (2010) Conditional expression of heterozygous or homozygous JAK2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115(17):3589\u20133597","journal-title":"Blood"},{"key":"170_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0092-8674(93)90415-M","volume":"74","author":"LS Argetsinger","year":"1993","unstructured":"Argetsinger LS et al (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74:237\u2013244","journal-title":"Cell"},{"key":"170_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"170_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","volume":"144","author":"PA Beer","year":"2009","unstructured":"Beer PA et al (2009) Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 144:904\u2013908","journal-title":"Br J Haematol"},{"key":"170_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","volume":"372","author":"D Bercovich","year":"2008","unstructured":"Bercovich D et al (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome. Lancet 372:1484\u20131492","journal-title":"Lancet"},{"key":"170_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood-2005-02-0707","volume":"106","author":"TJ Boggon","year":"2005","unstructured":"Boggon TJ, Li Y, Manley PW, Eck MJ (2005) Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog. Blood 106:996\u20131002","journal-title":"Blood"},{"key":"170_CR10","doi-asserted-by":"publisher","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","volume":"66","author":"TG Bumm","year":"2006","unstructured":"Bumm TG et al (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66:11156\u201311165","journal-title":"Cancer Res"},{"key":"170_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"170_CR12","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","volume":"108","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548\u20133555","journal-title":"Blood"},{"issue":"2","key":"170_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/leu.2009.218","volume":"24","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N et al (2009a) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 24(2):469\u2013473","journal-title":"Leukemia"},{"key":"170_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/leu.2009.141","volume":"23","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N et al (2009b) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183\u20132186","journal-title":"Leukemia"},{"key":"170_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","volume":"18","author":"E Chen","year":"2010","unstructured":"Chen E et al (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18:524\u2013535","journal-title":"Cancer Cell"},{"key":"170_CR16","doi-asserted-by":"publisher","first-page":"17588","DOI":"10.1074\/jbc.M512616200","volume":"281","author":"YS Cho","year":"2006","unstructured":"Cho YS, Kim EJ, Park UH, Sin HS, Um SJ (2006) Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 281:17588\u201317598","journal-title":"J Biol Chem"},{"key":"170_CR17","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289\u20132301","journal-title":"N Engl J Med"},{"key":"170_CR18","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","volume":"103","author":"J Ding","year":"2004","unstructured":"Ding J et al (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198\u20134200","journal-title":"Blood"},{"key":"170_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"170_CR20","doi-asserted-by":"publisher","first-page":"12941","DOI":"10.1074\/jbc.M709302200","volume":"283","author":"A Dusa","year":"2008","unstructured":"Dusa A et al (2008) Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 283:12941\u201312948","journal-title":"J Biol Chem"},{"key":"170_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722\u2013726","journal-title":"Nat Genet"},{"key":"170_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553\u2013567","journal-title":"Cancer Cell"},{"key":"170_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ydbio.2009.10.004","volume":"337","author":"CL Fisher","year":"2010","unstructured":"Fisher CL et al (2010) Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337:9\u201315","journal-title":"Dev Biol"},{"key":"170_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1084\/jem.20072182","volume":"205","author":"E Flex","year":"2008","unstructured":"Flex E et al (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205:751\u2013758","journal-title":"J Exp Med"},{"key":"170_CR25","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI31871","volume":"117","author":"SP Gao","year":"2007","unstructured":"Gao SP et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846\u20133856","journal-title":"J Clin Invest"},{"key":"170_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","volume":"145","author":"V Gelsi-Boyer","year":"2009","unstructured":"Gelsi-Boyer V et al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788\u2013800","journal-title":"Br J Haematol"},{"key":"170_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S et al (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339\u2013344","journal-title":"J Exp Med"},{"key":"170_CR28","first-page":"1347","volume":"7","author":"AG Harpur","year":"1992","unstructured":"Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7:1347\u20131353","journal-title":"Oncogene"},{"key":"170_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","volume":"16","author":"M Hedvat","year":"2009","unstructured":"Hedvat M et al (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487\u2013497","journal-title":"Cancer Cell"},{"key":"170_CR30","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","volume":"111","author":"EO Hexner","year":"2008","unstructured":"Hexner EO et al (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111:5663\u20135671","journal-title":"Blood"},{"key":"170_CR31","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"170_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446\u2013449","journal-title":"Nat Genet"},{"key":"170_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ng.342","volume":"41","author":"O Kilpivaara","year":"2009","unstructured":"Kilpivaara O et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455\u2013459","journal-title":"Nat Genet"},{"key":"170_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M et al (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839\u2013843","journal-title":"Nature"},{"issue":"14","key":"170_CR35","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","volume":"115","author":"P Koppikar","year":"2010","unstructured":"Koppikar P et al (2010) Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115(14):2919\u20132927","journal-title":"Blood"},{"key":"170_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","volume":"30","author":"R Kralovics","year":"2002","unstructured":"Kralovics R, Guan Y, Prchal JT (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30:229\u2013236","journal-title":"Exp Hematol"},{"key":"170_CR37","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"170_CR38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","volume":"108","author":"C Lacout","year":"2006","unstructured":"Lacout C et al (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652\u20131660","journal-title":"Blood"},{"key":"170_CR39","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","volume":"112","author":"O Landgren","year":"2008","unstructured":"Landgren O et al (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199\u20132204","journal-title":"Blood"},{"key":"170_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.391","volume":"41","author":"SM Langemeijer","year":"2009","unstructured":"Langemeijer SM et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838\u2013842","journal-title":"Nat Genet"},{"key":"170_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"170_CR42","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424\u20132433","journal-title":"N Engl J Med"},{"issue":"24","key":"170_CR43","first-page":"5741","volume":"30","author":"J Li","year":"2010","unstructured":"Li J et al (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 30(24):5741\u20135751","journal-title":"Blood"},{"key":"170_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","volume":"107","author":"IS Lucet","year":"2006","unstructured":"Lucet IS et al (2006) The structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor. Blood 107:176\u2013183","journal-title":"Blood"},{"key":"170_CR45","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","volume":"28","author":"G Marcucci","year":"2010","unstructured":"Marcucci G et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 28:2348\u20132355","journal-title":"J Clin Oncol"},{"key":"170_CR46","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058\u20131066","journal-title":"N Engl J Med"},{"key":"170_CR47","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","volume":"116","author":"C Marty","year":"2010","unstructured":"Marty C et al (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116:783\u2013787","journal-title":"Blood"},{"key":"170_CR48","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1172\/JCI42442","volume":"120","author":"S Marubayashi","year":"2010","unstructured":"Marubayashi S et al (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120:3578\u20133593","journal-title":"J Clin Invest"},{"key":"170_CR49","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA et al (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973\u2013977","journal-title":"Blood"},{"issue":"1","key":"170_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K et al (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20(1):11\u201324","journal-title":"Cancer Cell"},{"key":"170_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A et al (2010) Physiological JAK2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17:584\u2013596","journal-title":"Cancer Cell"},{"key":"170_CR52","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1073\/pnas.0811761106","volume":"106","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG et al (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106:9414\u20139418","journal-title":"Proc Natl Acad Sci USA"},{"key":"170_CR53","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G et al (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665\u2013667","journal-title":"Nat Genet"},{"key":"170_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","volume":"116","author":"ST Oh","year":"2010","unstructured":"Oh ST et al (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988\u2013992","journal-title":"Blood"},{"key":"170_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450\u2013454","journal-title":"Nat Genet"},{"key":"170_CR56","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1,182 patients. Blood 108:3472\u20133476","journal-title":"Blood"},{"key":"170_CR57","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 21:1658\u20131668","journal-title":"Leukemia"},{"issue":"7","key":"170_CR58","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A et al (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789\u2013796","journal-title":"J Clin Oncol"},{"key":"170_CR59","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","volume":"93","author":"E Parganas","year":"1998","unstructured":"Parganas E et al (1998) JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93:385\u2013395","journal-title":"Cell"},{"key":"170_CR60","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270","journal-title":"PLoS Med"},{"issue":"6","key":"170_CR61","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ccr.2011.05.005","volume":"19","author":"C Quivoron","year":"2011","unstructured":"Quivoron C et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 19(6):805\u2013813","journal-title":"Cancer Cell"},{"key":"170_CR62","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nature07475","volume":"457","author":"S Rebouissou","year":"2009","unstructured":"Rebouissou S et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457:200\u2013204","journal-title":"Nature"},{"key":"170_CR63","doi-asserted-by":"publisher","first-page":"47954","DOI":"10.1074\/jbc.M205156200","volume":"277","author":"P Saharinen","year":"2002","unstructured":"Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of JAK2 and JAK3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277:47954\u201347963","journal-title":"J Biol Chem"},{"key":"170_CR64","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","volume":"108","author":"LM Scott","year":"2006","unstructured":"Scott LM, Scott MA, Campbell PJ, Green AR (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108:2435\u20132437","journal-title":"Blood"},{"key":"170_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459\u2013468","journal-title":"N Engl J Med"},{"key":"170_CR66","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","volume":"208","author":"C Shochat","year":"2011","unstructured":"Shochat C et al (2011) Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 208:901\u2013908","journal-title":"J Exp Med"},{"key":"170_CR67","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930\u2013935","journal-title":"Science"},{"key":"170_CR68","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides A et al (2007) Leukemic blasts in transformed JAK2\u2013V617F-positive myeloproliferative disorders are frequently negative for the JAK2\u2013V617F mutation. Blood 110:375\u2013379","journal-title":"Blood"},{"key":"170_CR69","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt R et al (2008) Ratio of mutant JAK2\u2013V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111:3931\u20133940","journal-title":"Blood"},{"key":"170_CR70","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1182\/blood-2007-09-113027","volume":"111","author":"MH Tomasson","year":"2008","unstructured":"Tomasson MH et al (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111:4797\u20134808","journal-title":"Blood"},{"key":"170_CR71","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117\u20131127","journal-title":"N Engl J Med"},{"key":"170_CR72","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","volume":"114","author":"Y Wang","year":"2009","unstructured":"Wang Y et al (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114:5024\u20135033","journal-title":"Blood"},{"key":"170_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225\u2013234","journal-title":"Cancer Cell"},{"key":"170_CR74","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G Wernig","year":"2006","unstructured":"Wernig G et al (2006) Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274\u20134281","journal-title":"Blood"},{"key":"170_CR75","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig G et al (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311\u2013320","journal-title":"Cancer Cell"},{"key":"170_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","volume":"74","author":"BA Witthuhn","year":"1993","unstructured":"Witthuhn BA et al (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74:227\u2013236","journal-title":"Cell"},{"key":"170_CR77","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","volume":"111","author":"S Xing","year":"2008","unstructured":"Xing S et al (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111:5109\u20135117","journal-title":"Blood"},{"issue":"4","key":"170_CR78","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/ng.788","volume":"43","author":"XJ Yan","year":"2011","unstructured":"Yan XJ et al (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43(4):309\u2013315","journal-title":"Nat Genet"},{"issue":"1","key":"170_CR79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2009","unstructured":"Yoda A et al (2009) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 107(1):252\u2013257","journal-title":"Proc Natl Acad Sci USA"},{"key":"170_CR80","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","volume":"1","author":"VM Zaleskas","year":"2006","unstructured":"Zaleskas VM et al (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1:e18","journal-title":"PLoS ONE"},{"key":"170_CR81","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"}],"container-title":["Current Topics in Microbiology and Immunology","Therapeutic Kinase Inhibitors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2011_170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T01:47:58Z","timestamp":1675907278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2011_170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783642282959","9783642282966"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/82_2011_170","relation":{},"ISSN":["0070-217X"],"issn-type":[{"type":"print","value":"0070-217X"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"7 August 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}